Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been given an average rating of “Moderate Buy” by the nine ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $25.7143.

A number of equities analysts have recently issued reports on DAWN shares. JPMorgan Chase & Co. increased their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. TD Cowen started coverage on shares of Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating and a $34.00 price target on the stock. Finally, Zacks Research upgraded shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th.

Day One Biopharmaceuticals Stock Down 2.4%

Shares of NASDAQ:DAWN opened at $11.78 on Friday. Day One Biopharmaceuticals has a 52 week low of $5.64 and a 52 week high of $13.20. The company has a 50-day moving average price of $10.48 and a 200 day moving average price of $8.63. The company has a market cap of $1.21 billion, a P/E ratio of -7.75 and a beta of -1.26.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Adam Dubow sold 6,395 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $74,182.00. Following the sale, the insider directly owned 72,694 shares in the company, valued at approximately $843,250.40. The trade was a 8.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lauren Merendino sold 5,814 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $67,442.40. Following the completion of the transaction, the insider owned 60,157 shares of the company’s stock, valued at approximately $697,821.20. This represents a 8.81% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after acquiring an additional 1,029 shares in the last quarter. Federated Hermes Inc. acquired a new stake in shares of Day One Biopharmaceuticals in the third quarter valued at approximately $39,000. Quarry LP purchased a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth approximately $49,000. Ameritas Investment Partners Inc. increased its stake in shares of Day One Biopharmaceuticals by 44.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after purchasing an additional 2,264 shares in the last quarter. Finally, CWM LLC raised its position in shares of Day One Biopharmaceuticals by 32.4% during the 4th quarter. CWM LLC now owns 8,373 shares of the company’s stock worth $78,000 after purchasing an additional 2,051 shares during the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.